UCB GETS POSITIVE RESULTS FROM TWO CIMIZIA PHASE III STUDIES.UCB UCB - Ultraviolet Coronal Berkeley UCB - Unemployment Compensation Benefits UCB - Unit Control Block UCB - United Carolina Bank UCB - United Christian Broadcasters UCB - United Colors of Benetton (fashion brand) UCB - United Cricket Board UCB - Universal Chess Board UCB - Universal Commercial Bank UCB - Universidade Castello Branco (Castello Branco University, Rio de Janeiro, Brazil) UCB - Universidade Católica de Brasilia (Brazil) has announced positive top-line results for signs and symptoms from two new phase III studies for CIMZIA(TM) (certolizumab pegol), the first Fab' fragment anti-TNF (Tumor Necrosis Factor), in the treatment of rheumatoid 1. resembling rheumatism. 2. associated with rheumatoid arthritis. rheu·ma·toid (r   m arthritis. In both the RAPID 1 (027) and RAPID 2 (050) studies CIMZIA(TM), in combination with methotrexate MTX , demonstrated superiority to placebo, and a statistically significant improvement in the signs and symptoms of rheumatoid arthritis as measured by all American College of Rheumatology (ACR) scores: ACR20, 50, and 70. Further details on the results from the RAPID studies, including data on the prevention of structural damage, will be released during the first quarter of 2007. A toxic antimetabolite that acts as a folic acid antagonist, used as an antineoplastic agent and in the treatment of rheumatoid arthritis and psoriasis. Also called amethopterin. UCB also provided an update on the status of the US approval of CIMZIATM in the treatment of Crohn's disease Crohn's disease: see colitis.. UCB has received a Complete Response Letter from the United States Food and Drug Administration (FDA) requesting additional information and clarification on data submitted in its Biologics License Application (BLA) for the approval of CIMZIATM in Crohn's disease. "We have absolute confidence in both the efficacy and tolerability profile of CIMZIATM, and in gaining US approval" said Melanie Lee, executive vice president R&D for UCB. "We are extremely pleased by the rheumatoid arthritis results and will work closely with the FDA to clarify any questions that they have, or may have, regarding CIMZIATM for the treatment of Crohn's disease and rheumatoid arthritis." About UCB UCB is a global biopharmaceutical company dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy / respiratory diseases, immune and inflammatory disorders and oncology - UCB focuses on securing a leading position in severe disease categories. Employing over 8,300 people in 40 countries, it has worldwide headquarters located in Brussels, Belgium, UCB is listed on the Euronext Brussels Exchange. For more information, visit http://www.ucb-group.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion